# Neurogastrx, Inc.

> Neurogastrx is a Woburn, Massachusetts biopharmaceutical company developing therapies for gastrointestinal disorders rooted in the enteric nervous system. Its lead candidate, NG101, is an oral, peripherally acting dopamine D2 receptor antagonist (a proprietary mesylate salt of metopimazine) in late-stage development for gastroparesis and for the nausea and vomiting that limit GLP-1 weight-loss and diabetes drugs. Backed by roughly $105-125M from OrbiMed, 5AM Ventures and venBio, the company reported Phase 2 data in 2025 showing sizable reductions in GLP-1-induced nausea and vomiting.

- **Founded:** 2012
- **Headquarters:** Woburn, Massachusetts, United States
- **Founders:** Pankaj Jay Pasricha (Co-founder; Head of Scientific Advisory Board), Cyril De Colle (Co-founder; Chief Scientific Officer)
- **Team size:** Small (clinical-stage biotech; roughly 10-50 employees)
- **Products:** NG101
- **Notable:** Reported Phase 2 data in November 2025 showing NG101 reduced GLP-1 (semaglutide)-induced nausea incidence by 40% and vomiting incidence by 67% versus placebo., Presented positive results at ObesityWeek 2025., Announced positive proof-of-concept data for NG101 in GLP-1-associated nausea and vomiting in October 2024.

## Products & services

- **NG101** — An oral, small-molecule, peripherally acting dopamine D2 receptor antagonist - a proprietary mesylate salt of metopimazine - developed for gastroparesis (diabetic and idiopathic) and for nausea and vomiting induced by GLP-1 receptor agonists. It acts on the area postrema outside the blood-brain barrier, aiming to block nausea and vomiting without affecting the satiety center or causing CNS/cardiac side effects.

## Achievements

- Reported Phase 2 data in November 2025 showing NG101 reduced GLP-1 (semaglutide)-induced nausea incidence by 40% and vomiting incidence by 67% versus placebo.
- Presented positive results at ObesityWeek 2025.
- Announced positive proof-of-concept data for NG101 in GLP-1-associated nausea and vomiting in October 2024.
- Raised approximately $105-125M across Series A and Series B financings from top-tier life-science investors.
- Advanced NG101 through a Phase 2 gastroparesis trial (NCT04303195).

## Latest updates

- **2025-11** — Announced Phase 2 study showing significant reductions in nausea and vomiting induced by GLP-1 receptor agonist semaglutide (nausea -40%, vomiting -67%), presented at ObesityWeek 2025.
- **2024-10** — Announced positive proof-of-concept data for NG101 in reducing GLP-1-associated nausea and vomiting.
- **2021-08** — Secured $60M Series B financing and expanded its management team.

## Links

- Website: https://neurogastrx.com
- LinkedIn: http://www.linkedin.com/company/neurogastrx-inc-

---

Profile page: https://yespress.io/neurogastrx-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-18